Editorial: Drug allergy

Luciana K Tanno^{1

2

3}, Paul Whitaker⁴

Affiliations

¹ Desbrest Institute d'Epidémiologie et de Santé Publique, IDESP, University of Montpellier - INSERM.
² Department of Allergy, University Hospital of Montpellier.
³ WHO Collaborating Centre on Scientific Classification Support, Montpellier, France.
⁴ Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK.

Editorial

Luciana K Tanno et al. Curr Opin Allergy Clin Immunol. 2022.

. 2022 Aug 1;22(4):213-214.

doi: 10.1097/ACI.0000000000000832.

Luciana K Tanno^{1

2

3}, Paul Whitaker⁴

¹ Desbrest Institute d'Epidémiologie et de Santé Publique, IDESP, University of Montpellier - INSERM.
² Department of Allergy, University Hospital of Montpellier.
³ WHO Collaborating Centre on Scientific Classification Support, Montpellier, France.
⁴ Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK.

No abstract available

References

1. Joint Task Force on Practice Parameters; American Academy of Allergy AaIACoA, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol 2010; 105:259–273.
1. Line J, Thomson P, Naisbitt DJ. Pathology of T-cell-mediated drug hypersensitivity reactions and impact of tolerance mechanisms on patient susceptibility. Curr Opin Allergy Clin Immunol 2022; 22:226–233.
1. Vocanson M, Naisbitt DJ, Nicolas JF. Current perspective of the etiopathogenesis of delayed-type, and T-cell-mediated drug-related skin diseases. J Allergy Clin Immunol 2020; 145:1142–1144.
1. Bretscher PA. A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci USA 1999; 96:185–190.
1. Whitaker P, Naisbitt D, Peckham D. Nonimmediate beta-lactam reactions in patients with cystic fibrosis. Curr Opin Allergy Clin Immunol 2012; 12:369–375.